Leo Pharma prepares to manufacture promising new drug  

Danish pharmaceutical firm Leo Pharma is building a DKK 50 million production plant for a potentially groundbreaking respiratory disease drug

Denmark's third largest pharmaceutical company Leo Pharma (formerly Leo Pharmaceuticals) has begun construction of new manufacturing facilities in Esbjerg, Jutland. The plant is slated to produce a promising new drug for respiratory disease. Leo has just commenced final clinical trials of the drug, involving around 1000 patients in 14 countries. If all goes well, Leo Pharma could be bringing the drug to market by the end of 2005. It is indicated for a life threatening condition known as ARDS, or Acute Respiratory Distress Syndrome. The news is reported in Jyllands-Posten.


The factory in Esbjerg, a bustling harbour town on the west coast of Jutland, is expected to cost up to DKK 50 million (USD 7 million) to construct. The European Health Authorities are also showing their support for the product, codenamed HL-10, by granting it Orphan Drug Status (drugs for treatment of rare diseases), which means that Leo Pharma will have exclusive sales rights in Europe for 10 years. That is also a necessity, says Leo Pharma's Research Director, because [HL-10] will be used on a relatively small patient group and so it will take several years to recover the investment.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×